MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

MDT

95.31

-1.26%↓

VEEV

287.1

-0.28%↓

A

139.44

+0.99%↑

HQY

92.23

-1.52%↓

TLRY

1.67

+5.03%↑

Search

Anavex Life Sciences Corp

Cerrado

SectorSalud

9.03 2.73

Resumen

Variación precio

24h

Actual

Mínimo

8.61

Máximo

9.07

Métricas clave

By Trading Economics

Ingresos

-2M

-13M

Empleados

42

EBITDA

-2.1M

-13M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+377.27% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-229M

740M

Apertura anterior

6.3

Cierre anterior

9.03

Noticias sobre sentimiento de mercado

By Acuity

89%

11%

355 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Anavex Life Sciences Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 oct 2025, 22:33 UTC

Ganancias

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 oct 2025, 22:21 UTC

Principales Movimientos del Mercado

Dentsply Sirona Shares Rise After SEC Probe Ends

14 oct 2025, 19:27 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 oct 2025, 17:56 UTC

Principales Movimientos del Mercado

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 oct 2025, 23:38 UTC

Charlas de Mercado

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 oct 2025, 22:12 UTC

Charlas de Mercado
Ganancias

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 oct 2025, 21:40 UTC

Ganancias

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 oct 2025, 21:39 UTC

Ganancias

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 oct 2025, 21:38 UTC

Ganancias

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 oct 2025, 21:06 UTC

Ganancias

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

14 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

14 oct 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

14 oct 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Health Care Roundup: Market Talk

14 oct 2025, 20:13 UTC

Ganancias

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 oct 2025, 20:01 UTC

Ganancias

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 oct 2025, 19:21 UTC

Charlas de Mercado
Ganancias

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 oct 2025, 19:12 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 oct 2025, 19:08 UTC

Charlas de Mercado

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 oct 2025, 18:59 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 oct 2025, 18:58 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 oct 2025, 18:58 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 oct 2025, 18:56 UTC

Adquisiciones, fusiones, absorciones

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 oct 2025, 18:46 UTC

Ganancias

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 oct 2025, 18:04 UTC

Ganancias

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 oct 2025, 18:01 UTC

Charlas de Mercado

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 oct 2025, 17:54 UTC

Ganancias

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 oct 2025, 17:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

14 oct 2025, 17:50 UTC

Charlas de Mercado

Lower Dollar Provides Some Strength in Grains -- Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp Esperado

Precio Objetivo

By TipRanks

377.27% repunte

Estimación a 12 meses

Media 42 USD  377.27%

Máximo 42 USD

Mínimo 42 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

355 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat